Genetic and pharmacological PARP inhibition reduces axonal degeneration in C. elegans models of ALS

Abstract excerpt

Axonal degeneration is observed in early stages of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). This degeneration generally precedes apoptosis and therefore may be a promising therapeutic target. An increasing number of genes have been identified to actively regulate axonal degeneration and regeneration; however, only a few potential therapeutic targets have been identified...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Neurodegenerative Diseases
• Share to Parkinson's Disease Mechanisms and Treatments
• Share to PARP inhibition in cancer therapy